S
Syndax Pharmaceuticals, Inc. (SNDX)
NMS – Real Time Price. Currency in USD
20.41
-0.97 (-4.54%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
20.41
-0.97 (-4.54%)
At close: May 12, 2026, 4:00 PM EDT
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Michael Downes Ph.D. | Co-Founder |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Mr. Keith Alan Goldan CPA | CFO, Treasurer & Principal Accounting Officer |
| Mr. Kevin McManus | Chief People Officer |
| Mr. Luke J. Albrecht J.D. | Senior VP, General Counsel & Secretary |
| Mr. Michael A. Metzger M.B.A. | CEO & Director |
| Mr. Steven Closter | Chief Commercial Officer |
| Sharon Klahre | Vice President of Investor Relations & Communications |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | sndx-20260430.htm |
| 2026-04-30 | 8-K | sndx-20260430.htm |
| 2026-02-26 | S-8 | sndx-20260226.htm |
| 2026-01-12 | 8-K | sndx-20260112.htm |
| 2025-12-19 | 8-K | sndx-20251218.htm |
| 2025-11-03 | 8-K | sndx-20251103.htm |
| 2025-10-24 | 8-K | sndx-20251024.htm |
| 2025-08-04 | 8-K | sndx-20250804.htm |
| 2025-08-04 | 10-Q | sndx-20250630.htm |
| 2025-06-26 | 8-K | sndx-20250624.htm |